New Zealand markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
985.02+4.45 (+0.45%)
At close: 04:00PM EDT
979.71 -5.31 (-0.54%)
Pre-market: 07:00AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 108.53B
Enterprise value 100.72B
Trailing P/E 29.08
Forward P/E 22.37
PEG ratio (5-yr expected) 1.62
Price/sales (ttm)8.57
Price/book (mrq)4.02
Enterprise value/revenue 7.69
Enterprise value/EBITDA 22.14

Trading information

Stock price history

Beta (5Y monthly) 0.17
52-week change 335.19%
S&P500 52-week change 326.14%
52-week high 3998.33
52-week low 3684.81
50-day moving average 3944.85
200-day moving average 3885.95

Share statistics

Avg vol (3-month) 3441.96k
Avg vol (10-day) 3351.29k
Shares outstanding 5108.37M
Implied shares outstanding 6110.19M
Float 8103.32M
% held by insiders 11.59%
% held by institutions 189.85%
Shares short (15 May 2024) 41.63M
Short ratio (15 May 2024) 43.4
Short % of float (15 May 2024) 41.56%
Short % of shares outstanding (15 May 2024) 41.48%
Shares short (prior month 15 Apr 2024) 41.39M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 29.45%
Operating margin (ttm)24.12%

Management effectiveness

Return on assets (ttm)7.74%
Return on equity (ttm)15.28%

Income statement

Revenue (ttm)13.1B
Revenue per share (ttm)122.57
Quarterly revenue growth (yoy)-0.50%
Gross profit (ttm)N/A
Net income avi to common (ttm)3.86B
Diluted EPS (ttm)33.88
Quarterly earnings growth (yoy)-11.70%

Balance sheet

Total cash (mrq)10.52B
Total cash per share (mrq)97.51
Total debt (mrq)2.7B
Total debt/equity (mrq)10.02%
Current ratio (mrq)5.27
Book value per share (mrq)250.15

Cash flow statement

Operating cash flow (ttm)4.74B
Levered free cash flow (ttm)3.03B